Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

A Phase 1 and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients With Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors.

Kieran MW, Geoerger B, Dunkel IJ, Broniscer A, Hargrave DR, Hingorani P, Aerts I, Bertozzi AI, Cohen KJ, Hummel TR, Shen V, Bouffet E, Pratilas CA, Pearson ADJ, Tseng L, Nebot N, Green S, Russo MW, Whitlock J.

Clin Cancer Res. 2019 Sep 10. pii: clincanres.3572.2017. doi: 10.1158/1078-0432.CCR-17-3572. [Epub ahead of print]

PMID:
31506385
2.

A Potential Role For Apparent Diffusion Coefficient in the Diagnosis of Trilateral Retinoblastoma.

Farouk Sait S, Haque S, Karimi S, Rebeiz KJ, Francis JH, Marr BP, Abramson DH, Souweidane MM, Dunkel IJ.

J Pediatr Hematol Oncol. 2019 Jun 27. doi: 10.1097/MPH.0000000000001523. [Epub ahead of print]

PMID:
31259824
3.

Kinetics of Xist-induced gene silencing can be predicted from combinations of epigenetic and genomic features.

Barros de Andrade E Sousa L, Jonkers I, Syx L, Dunkel I, Chaumeil J, Picard C, Foret B, Chen CJ, Lis JT, Heard E, Schulz EG, Marsico A.

Genome Res. 2019 Jul;29(7):1087-1099. doi: 10.1101/gr.245027.118. Epub 2019 Jun 7.

4.

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M.

Lancet Oncol. 2019 Jul;20(7):1011-1022. doi: 10.1016/S1470-2045(19)30277-3. Epub 2019 May 28.

PMID:
31151904
5.

A symmetric toggle switch explains the onset of random X inactivation in different mammals.

Mutzel V, Okamoto I, Dunkel I, Saitou M, Giorgetti L, Heard E, Schulz EG.

Nat Struct Mol Biol. 2019 May;26(5):350-360. doi: 10.1038/s41594-019-0214-1. Epub 2019 Apr 8.

PMID:
30962582
6.

Quantifying radiation therapy response using apparent diffusion coefficient (ADC) parametric mapping of pediatric diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium.

Ceschin R, Kocak M, Vajapeyam S, Pollack IF, Onar-Thomas A, Dunkel IJ, Poussaint TY, Panigrahy A.

J Neurooncol. 2019 May;143(1):79-86. doi: 10.1007/s11060-019-03133-y. Epub 2019 Feb 27.

PMID:
30810873
7.

A recurrent novel MGA-NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcoma.

Diolaiti D, Dela Cruz FS, Gundem G, Bouvier N, Boulad M, Zhang Y, Chou AJ, Dunkel IJ, Sanghvi R, Shah M, Geiger H, Rahman S, Felice V, Wrzeszczynski KO, Darnell RB, Antonescu CR, French CA, Papaemmanuil E, Kung AL, Shukla N.

Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6). pii: a003194. doi: 10.1101/mcs.a003194. Print 2018 Dec.

8.

A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis.

Chellapandian D, Hines MR, Zhang R, Jeng M, van den Bos C, Santa-María López V, Lehmberg K, Sieni E, Wang Y, Nakano T, Williams JA, Fustino NJ, Astigarraga I, Dunkel IJ, Abla O, van Halteren AGS, Pei D, Cheng C, Weitzman S, Sung L, Nichols KE.

Cancer. 2019 Mar 15;125(6):963-971. doi: 10.1002/cncr.31893. Epub 2018 Dec 6.

PMID:
30521100
9.

Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the "head-start" I and II clinical trials.

Osorio DS, Patel N, Ji L, Sposto R, Stanek J, Gardner SL, Allen JC, Cornelius A, McCowage GB, Termuhlen A, Dunkel IJ, Comito M, Garvin J, Finlay JL.

J Neurooncol. 2018 Dec;140(3):717-725. doi: 10.1007/s11060-018-03003-z. Epub 2018 Nov 3.

PMID:
30392092
10.

Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017.

Lu JE, Francis JH, Dunkel IJ, Shields CL, Yu MD, Berry JL, Kogachi K, Skalet AH, Miller AK, Santapuram PR, Daniels AB, Abramson DH.

Br J Ophthalmol. 2019 Sep;103(9):1272-1277. doi: 10.1136/bjophthalmol-2018-312915. Epub 2018 Oct 25.

PMID:
30361279
11.

Current Treatment of Bilateral Retinoblastoma: The Impact of Intraarterial and Intravitreous Chemotherapy.

Francis JH, Roosipu N, Levin AM, Brodie SE, Dunkel IJ, Gobin YP, Abramson DH.

Neoplasia. 2018 Aug;20(8):757-763. doi: 10.1016/j.neo.2018.05.007. Epub 2018 Jun 22.

12.

Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial.

Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NV, Larson SM, Dunkel IJ.

Lancet Oncol. 2018 Aug;19(8):1040-1050. doi: 10.1016/S1470-2045(18)30322-X. Epub 2018 Jun 18. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382.

13.

A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.

Wang J, Yao Z, Jonsson P, Allen AN, Qin ACR, Uddin S, Dunkel IJ, Petriccione M, Manova K, Haque S, Rosenblum MK, Pisapia DJ, Rosen N, Taylor BS, Pratilas CA.

Cancer Discov. 2018 Sep;8(9):1130-1141. doi: 10.1158/2159-8290.CD-17-1263. Epub 2018 Jun 7.

14.

Vision-Targeted Health-Related Quality of Life in Adult Survivors of Retinoblastoma.

Friedman DN, Chou JF, Francis JH, Sklar CA, Li Y, McCabe M, Robison LL, Kleinerman RA, Oeffinger KC, Abramson DH, Dunkel IJ, Ford JS.

JAMA Ophthalmol. 2018 Jun 1;136(6):637-641. doi: 10.1001/jamaophthalmol.2018.1082.

15.

Total retinal detachments due to retinoblastoma: Outcomes following intra-arterial chemotherapy/ophthalmic artery chemosurgery.

Rowlands MA, Mondesire-Crump I, Levin A, Mauguen A, Francis JH, Dunkel IJ, Brodie SE, Gobin YP, Abramson DH.

PLoS One. 2018 Apr 26;13(4):e0195395. doi: 10.1371/journal.pone.0195395. eCollection 2018.

16.

Patterns of relapse for children with localized intracranial ependymoma.

De B, Khakoo Y, Souweidane MM, Dunkel IJ, Patel SH, Gilheeney SW, De Braganca KC, Karajannis MA, Wolden SL.

J Neurooncol. 2018 Jun;138(2):435-445. doi: 10.1007/s11060-018-2815-7. Epub 2018 Mar 6.

PMID:
29511977
17.

BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.

Chisholm JC, Suvada J, Dunkel IJ, Casanova M, Zhang W, Ritchie N, Choi Y, Park J, Das Thakur M, Simko S, Wan Rachel Tam N, Ferrari A.

Pediatr Blood Cancer. 2018 May;65(5):e26947. doi: 10.1002/pbc.26947. Epub 2018 Jan 19.

18.

Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.

Geoerger B, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, Brochez L, Cruz O, Nysom K, Berghorn E, Simsek B, Shen J, Pappo A.

Eur J Cancer. 2017 Nov;86:358-363. doi: 10.1016/j.ejca.2017.09.032. Epub 2017 Nov 5.

PMID:
29100190
19.

Long-term outcomes of adult medulloblastoma patients treated with radiotherapy.

De B, Beal K, De Braganca KC, Souweidane MM, Dunkel IJ, Khakoo Y, Gilheeney SW, DeAngelis LM, Menzel P, Patel SH, Wolden SL.

J Neurooncol. 2018 Jan;136(1):95-104. doi: 10.1007/s11060-017-2627-1. Epub 2017 Oct 10.

20.

A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma.

Kramer K, Pandit-Taskar N, Humm JL, Zanzonico PB, Haque S, Dunkel IJ, Wolden SL, Donzelli M, Goldman DA, Lewis JS, Lyashchenko SK, Khakoo Y, Carrasquillo JA, Souweidane MM, Greenfield JP, Lyden D, De Braganca KD, Gilheeney SW, Larson SM, Cheung NV.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26754. Epub 2017 Sep 22.

21.

The Effect of Ophthalmic Artery Chemosurgery on Immune Function in Retinoblastoma Patients: A Single Institution Retrospective Analysis.

Fischer C, Petriccione M, Vitolano S, Guarini E, Davis ME, Dunkel IJ.

J Pediatr Hematol Oncol. 2017 Oct;39(7):555-559. doi: 10.1097/MPH.0000000000000968.

22.

Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies.

Osorio DS, Dunkel IJ, Cervone KA, Goyal RK, Steve Lo KM, Finlay JL, Gardner SL.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26776. Epub 2017 Sep 14.

PMID:
28905508
23.

Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26699. Epub 2017 Jul 27.

24.

Reduced-volume radiotherapy for patients with localized intracranial nongerminoma germ cell tumors.

De B, Cahlon O, Dunkel IJ, De Braganca KC, Khakoo Y, Gilheeney SW, Souweidane MM, Wolden SL.

J Neurooncol. 2017 Sep;134(2):349-356. doi: 10.1007/s11060-017-2532-7. Epub 2017 Jun 28.

25.

Second primary malignancies in retinoblastoma patients treated with intra-arterial chemotherapy: the first 10 years.

Habib LA, Francis JH, Fabius AW, Gobin PY, Dunkel IJ, Abramson DH.

Br J Ophthalmol. 2018 Feb;102(2):272-275. doi: 10.1136/bjophthalmol-2017-310328. Epub 2017 Jun 9.

PMID:
28600304
26.

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.

Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, Trippett TM, Gilheeney SW, Khakoo Y, Lyden DC, De Braganca KC, Kolesar JM, Huse JT, Kramer K, Cheung NV, Dunkel IJ.

PLoS One. 2017 Jun 5;12(6):e0178593. doi: 10.1371/journal.pone.0178593. eCollection 2017.

27.

A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.

Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald TJ, Smith AA, Etzl MM, Kuei MC, Donson AM, Gore L, DiRenzo J, Trippett TM, Ostrovnaya I, Narendran A, Foreman NK, Dunkel IJ.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26621. Epub 2017 May 24.

28.

Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma.

Abramson DH, Fabius AW, Francis JH, Marr BP, Dunkel IJ, Brodie SE, Escuder A, Gobin YP.

Ophthalmic Genet. 2017 Jan-Feb;38(1):16-21. doi: 10.1080/13816810.2016.1244695. Epub 2017 Jan 17.

29.

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.

Becher OJ, Gilheeney SW, Khakoo Y, Lyden DC, Haque S, De Braganca KC, Kolesar JM, Huse JT, Modak S, Wexler LH, Kramer K, Spasojevic I, Dunkel IJ.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26409. Epub 2016 Dec 30.

PMID:
28035748
30.

A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.

Arceci RJ, Allen CE, Dunkel IJ, Jacobsen E, Whitlock J, Vassallo R, Morris SR, Portnoy A, Reedy BA, Smith DA, Noble R, Murnane A, Cornfeld M, Rodriguez-Galindo C, Heaney ML, McClain K, Vaiselbuh S.

Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26325. Epub 2016 Nov 2.

PMID:
27804235
31.

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ.

Int J Cancer. 2017 Jan 15;140(2):480-484. doi: 10.1002/ijc.30440. Epub 2016 Sep 30.

32.

reChIP-seq reveals widespread bivalency of H3K4me3 and H3K27me3 in CD4(+) memory T cells.

Kinkley S, Helmuth J, Polansky JK, Dunkel I, Gasparoni G, Fröhler S, Chen W, Walter J, Hamann A, Chung HR.

Nat Commun. 2016 Aug 17;7:12514. doi: 10.1038/ncomms12514.

33.

Comparative DNA methylation and gene expression analysis identifies novel genes for structural congenital heart diseases.

Grunert M, Dorn C, Cui H, Dunkel I, Schulz K, Schoenhals S, Sun W, Berger F, Chen W, Sperling SR.

Cardiovasc Res. 2016 Oct;112(1):464-77. doi: 10.1093/cvr/cvw195. Epub 2016 Aug 5.

PMID:
27496870
34.

Psychiatric manifestations as initial presentation for pediatric CNS germ cell tumors, a case series.

Malbari F, Gershon TR, Garvin JH, Allen JC, Khakoo Y, Levy AS, Dunkel IJ.

Childs Nerv Syst. 2016 Aug;32(8):1359-62. doi: 10.1007/s00381-016-3145-8. Epub 2016 Jun 16.

35.

Simultaneous Bilateral Ophthalmic Artery Chemosurgery for Bilateral Retinoblastoma (Tandem Therapy).

Abramson DH, Marr BP, Francis JH, Dunkel IJ, Fabius AW, Brodie SE, Mondesire-Crump I, Gobin YP.

PLoS One. 2016 Jun 3;11(6):e0156806. doi: 10.1371/journal.pone.0156806. eCollection 2016.

36.

PHF13 is a molecular reader and transcriptional co-regulator of H3K4me2/3.

Chung HR, Xu C, Fuchs A, Mund A, Lange M, Staege H, Schubert T, Bian C, Dunkel I, Eberharter A, Regnard C, Klinker H, Meierhofer D, Cozzuto L, Winterpacht A, Di Croce L, Min J, Will H, Kinkley S.

Elife. 2016 May 25;5. pii: e10607. doi: 10.7554/eLife.10607.

37.

Meningioma after radiotherapy for malignancy.

Morgenstern PF, Shah K, Dunkel IJ, Reiner AS, Khakoo Y, Rosenblum MK, Gutin P.

J Clin Neurosci. 2016 Aug;30:93-97. doi: 10.1016/j.jocn.2016.02.002. Epub 2016 Apr 8.

38.

Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.

Lulla RR, Goldman S, Yamada T, Beattie CW, Bressler L, Pacini M, Pollack IF, Fisher PG, Packer RJ, Dunkel IJ, Dhall G, Wu S, Onar A, Boyett JM, Fouladi M.

Neuro Oncol. 2016 Sep;18(9):1319-25. doi: 10.1093/neuonc/now047. Epub 2016 Mar 28.

39.

Twenty-Year Collaboration Between North American and South American Retinoblastoma Programs.

Chantada GL, Dunkel IJ, Schaiquevich PS, Grynszpancholc EL, Francis J, Ceciliano A, Zubizarreta PA, Fandiño AC, Abramson DH.

J Glob Oncol. 2016 Mar 30;2(6):347-352. doi: 10.1200/JGO.2015.002782. eCollection 2016 Dec. No abstract available.

40.

Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma.

Abramson DH, Daniels AB, Marr BP, Francis JH, Brodie SE, Dunkel IJ, Gobin YP.

PLoS One. 2016 Jan 12;11(1):e0146582. doi: 10.1371/journal.pone.0146582. eCollection 2016.

41.

Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study.

Friedman DN, Chou JF, Oeffinger KC, Kleinerman RA, Ford JS, Sklar CA, Li Y, McCabe MS, Robison LL, Marr BP, Abramson DH, Dunkel IJ.

Cancer. 2016 Mar 1;122(5):773-81. doi: 10.1002/cncr.29704. Epub 2016 Jan 11.

42.

Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC.

Abramson DH, Fabius AW, Issa R, Francis JH, Marr BP, Dunkel IJ, Gobin YP.

PLoS One. 2015 Dec 28;10(12):e0145436. doi: 10.1371/journal.pone.0145436. eCollection 2015.

43.

Intensity-Modulated Radiation Therapy With Dose Painting: A Brain-Sparing Technique for Intracranial Germ Cell Tumors.

Yang JC, Terezakis SA, Dunkel IJ, Gilheeney SW, Wolden SL.

Pediatr Blood Cancer. 2016 Apr;63(4):646-51. doi: 10.1002/pbc.25867. Epub 2015 Dec 24.

44.

INTRAVITREAL MELPHALAN AS SALVAGE THERAPY FOR REFRACTORY RETINAL AND SUBRETINAL RETINOBLASTOMA.

Francis JH, Marr BP, Brodie SE, Gobin P, Dunkel IJ, Abramson DH.

Retin Cases Brief Rep. 2016 Fall;10(4):357-60. doi: 10.1097/ICB.0000000000000262.

45.

Phosphorylation of the chromatin remodeling factor DPF3a induces cardiac hypertrophy through releasing HEY repressors from DNA.

Cui H, Schlesinger J, Schoenhals S, Tönjes M, Dunkel I, Meierhofer D, Cano E, Schulz K, Berger MF, Haack T, Abdelilah-Seyfried S, Bulyk ML, Sauer S, Sperling SR.

Nucleic Acids Res. 2016 Apr 7;44(6):2538-53. doi: 10.1093/nar/gkv1244. Epub 2015 Nov 17.

46.

Psychosocial Outcomes in Adult Survivors of Retinoblastoma.

Ford JS, Chou JF, Sklar CA, Oeffinger KC, Novetsky Friedman D, McCabe M, Robison LL, Kleinerman RA, Li Y, Marr BP, Abramson DH, Dunkel IJ.

J Clin Oncol. 2015 Nov 1;33(31):3608-14. doi: 10.1200/JCO.2014.60.5733. Epub 2015 Sep 28.

47.

Enucleation vs Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma: A Retrospective Analysis.

Yannuzzi NA, Francis JH, Marr BP, Belinsky I, Dunkel IJ, Gobin YP, Abramson DH.

JAMA Ophthalmol. 2015 Sep;133(9):1062-6. doi: 10.1001/jamaophthalmol.2015.2243.

48.

Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group.

Cohen BH, Geyer JR, Miller DC, Curran JG, Zhou T, Holmes E, Ingles SA, Dunkel IJ, Hilden J, Packer RJ, Pollack IF, Gajjar A, Finlay JL; Children's Oncology Group.

Pediatr Neurol. 2015 Jul;53(1):31-46. doi: 10.1016/j.pediatrneurol.2015.03.019. Epub 2015 Apr 9.

49.

Retinoblastoma.

Ortiz MV, Dunkel IJ.

J Child Neurol. 2016 Feb;31(2):227-36. doi: 10.1177/0883073815587943. Epub 2015 May 28. Review.

PMID:
26023180
50.

Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis.

Stanelle EJ, Busam KJ, Rich BS, Christison-Lagay ER, Dunkel IJ, Marghoob AA, Halpern A, Coit DG, La Quaglia MP.

J Pediatr Surg. 2015 Jun;50(6):1019-23. doi: 10.1016/j.jpedsurg.2015.03.030. Epub 2015 Mar 14.

Supplemental Content

Loading ...
Support Center